Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the European Medicines Agency has approved the purification of REPLAGAL® (agalsidase alfa) drug substance at its new manufacturing facility in Lexington, MA, US. REPLAGAL, Shire’s enzyme replacement therapy for the treatment of Fabry disease is the first product that will be made available to patients from the new facility.
With this approval, the company now has two approved facilities – Alewife, which is located in Cambridge, MA, as well as the new Lexington facility – in which to purify REPLAGAL, thus providing increased manufacturing flexibility. The cell culture portion of the REPLAGAL manufacturing process will continue to be conducted at Alewife.
“We are pleased that we were able to accelerate the construction and approval of our new manufacturing facility in order to provide rapid access to important therapies for patients in need,” said Bill Ciambrone, Senior Vice President of Technical Operations, Shire HGT. “This new facility allows greater flexibility to meet global demand for our products, including REPLAGAL.”
Shire reiterated that it has sufficient product inventory to continue to meet the needs of Fabry patients worldwide currently receiving REPLAGAL and that it can meet anticipated additional demand. The Company is committed to continuing to provide uninterrupted long-term access to the product at the licensed dose.
In addition to REPLAGAL, Shire anticipates regulatory agency submission of the VPRIV (velaglucerase alfa) manufacturing process at the new Lexington manufacturing facility by the end of 2011.
For further information please contact:
|Investor Relations||Eric Rojas ([email protected])||+1 781 482 0999|
|Sarah Elton-Farr ([email protected])||+44 1256 894 157|
|Media||Jessica Mann ([email protected])||+44 1256 894 280|
|Jessica Cotrone ([email protected])||+1 781 482 9538|
Notes to editors
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.